AR035557A1 - Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivado - Google Patents
Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivadoInfo
- Publication number
- AR035557A1 AR035557A1 ARP000104118A ARP000104118A AR035557A1 AR 035557 A1 AR035557 A1 AR 035557A1 AR P000104118 A ARP000104118 A AR P000104118A AR P000104118 A ARP000104118 A AR P000104118A AR 035557 A1 AR035557 A1 AR 035557A1
- Authority
- AR
- Argentina
- Prior art keywords
- arylamino
- alkyl
- aryloxylalkyl
- aryl
- cycloalkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- -1 carboxy, amino Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- XAEGRAIWWBXIRR-UHFFFAOYSA-N 1h-pyrazol-5-ylurea Chemical class NC(=O)NC=1C=CNN=1 XAEGRAIWWBXIRR-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000005014 aminoalkynyl group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000005325 aryloxy aryl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/372,833 US6387900B1 (en) | 1999-08-12 | 1999-08-12 | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035557A1 true AR035557A1 (es) | 2004-06-16 |
Family
ID=23469810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104118A AR035557A1 (es) | 1999-08-12 | 2000-08-10 | Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivado |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6387900B1 (enExample) |
| EP (1) | EP1202734B1 (enExample) |
| JP (1) | JP2003507328A (enExample) |
| KR (1) | KR20020060158A (enExample) |
| CN (1) | CN1379668A (enExample) |
| AR (1) | AR035557A1 (enExample) |
| AT (1) | ATE361070T1 (enExample) |
| AU (1) | AU6747000A (enExample) |
| BR (1) | BR0013277A (enExample) |
| CA (1) | CA2380786A1 (enExample) |
| CO (1) | CO5200848A1 (enExample) |
| DE (1) | DE60034683T2 (enExample) |
| EA (1) | EA200200249A1 (enExample) |
| ES (1) | ES2284518T3 (enExample) |
| HK (1) | HK1049790A1 (enExample) |
| HU (1) | HUP0301857A2 (enExample) |
| IL (1) | IL147925A0 (enExample) |
| MX (1) | MXPA02001497A (enExample) |
| NO (1) | NO20020687L (enExample) |
| NZ (1) | NZ517238A (enExample) |
| PE (1) | PE20010482A1 (enExample) |
| PL (1) | PL354058A1 (enExample) |
| SK (1) | SK2082002A3 (enExample) |
| WO (1) | WO2001012188A1 (enExample) |
| ZA (1) | ZA200201118B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| HUP0203895A3 (en) | 1999-12-24 | 2004-09-28 | Aventis Pharma Ltd West Mallin | Substituted azaindoles and pharmaceutical compositions containing them and their use |
| WO2001057034A1 (en) | 2000-02-07 | 2001-08-09 | Bristol-Myers Squibb Co. | 3-aminopyrazole inhibitors of cyclin dependent kinases |
| AU2001253540A1 (en) | 2000-04-25 | 2001-11-07 | Bristol-Myers Squibb Company | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors |
| DZ3398A1 (fr) * | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| AU2002215053A1 (en) * | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2305255B1 (en) * | 2001-12-03 | 2012-08-22 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| KR20030071029A (ko) * | 2002-02-27 | 2003-09-03 | 주식회사 팜제니아 | 항암제 및 방사선 치료 증진제로서 유용한 조성물 |
| US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| DE10221052A1 (de) * | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
| WO2003097610A1 (en) * | 2002-05-17 | 2003-11-27 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1542667B1 (en) | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| CA2495284A1 (en) * | 2002-09-05 | 2004-03-18 | Neurosearch A/S | Diarylurea derivatives and their use as chloride channel blockers |
| JP2006504725A (ja) | 2002-10-09 | 2006-02-09 | ファイザー・プロダクツ・インク | 神経変性障害治療用ピラゾール化合物 |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| GB0305426D0 (en) * | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| ES2436524T3 (es) | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| EP1609789A1 (en) * | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| AU2005273612B2 (en) * | 2004-08-12 | 2010-10-14 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
| US7429800B2 (en) * | 2005-06-30 | 2008-09-30 | Sabic Innovative Plastics Ip B.V. | Molding composition and method, and molded article |
| JP5303271B2 (ja) | 2005-07-19 | 2013-10-02 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物 |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| US20090118336A1 (en) * | 2006-05-03 | 2009-05-07 | Laurent David | Pyrazole derivatives and their use as pi3k inhibitors |
| WO2008046919A2 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| JP5675343B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| JP2010528114A (ja) * | 2007-05-25 | 2010-08-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ |
| EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| AU2009310352A1 (en) * | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| EP3025724B1 (en) | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| US20130109019A1 (en) * | 2010-07-02 | 2013-05-02 | Adrian E. Murillo | Hapten conjugates for target detection |
| WO2012022487A1 (de) * | 2010-08-20 | 2012-02-23 | Grünenthal GmbH | Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
| BR112013008527A2 (pt) | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| NZ618795A (en) | 2011-05-13 | 2015-07-31 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| CA2891334C (en) | 2012-11-13 | 2021-10-19 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
| WO2014078331A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| ME02990B (me) | 2012-11-13 | 2018-10-20 | Array Biopharma Inc | Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| CA2906157C (en) | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| JP6430483B2 (ja) | 2013-03-15 | 2018-11-28 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 化学療法の間の正常細胞の一時的な保護 |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| CN106459013B (zh) | 2014-05-15 | 2019-10-25 | 阵列生物制药公司 | 作为trka激酶抑制剂的化合物及其用途 |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| MA56193A (fr) * | 2019-06-14 | 2022-04-20 | Ifm Due Inc | Composés et compositions pour traiter des états associés à une activité de sting |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Ｃｄｋ２抑制劑及其製備方法 |
| JP2024502474A (ja) | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物 |
| CN117843563A (zh) * | 2024-01-02 | 2024-04-09 | 沈阳药科大学 | 含脲片段的CDKs抑制剂衍生物及其药物组合物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
| US3646059A (en) * | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
| CA2203517A1 (en) | 1994-11-10 | 1996-05-23 | Alan M. Laibelman | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| US6043246A (en) | 1996-12-03 | 2000-03-28 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
| US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| CA2315720A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
-
1999
- 1999-08-12 US US09/372,833 patent/US6387900B1/en not_active Expired - Fee Related
-
2000
- 2000-08-03 PE PE2000000771A patent/PE20010482A1/es not_active Application Discontinuation
- 2000-08-10 AR ARP000104118A patent/AR035557A1/es unknown
- 2000-08-10 CO CO00059913A patent/CO5200848A1/es not_active Application Discontinuation
- 2000-08-11 AU AU67470/00A patent/AU6747000A/en not_active Abandoned
- 2000-08-11 DE DE60034683T patent/DE60034683T2/de not_active Expired - Fee Related
- 2000-08-11 HK HK03101874.6A patent/HK1049790A1/zh unknown
- 2000-08-11 PL PL00354058A patent/PL354058A1/xx not_active Application Discontinuation
- 2000-08-11 EA EA200200249A patent/EA200200249A1/ru unknown
- 2000-08-11 CN CN00812736A patent/CN1379668A/zh active Pending
- 2000-08-11 IL IL14792500A patent/IL147925A0/xx unknown
- 2000-08-11 EP EP00955241A patent/EP1202734B1/en not_active Expired - Lifetime
- 2000-08-11 BR BR0013277-2A patent/BR0013277A/pt not_active Application Discontinuation
- 2000-08-11 CA CA002380786A patent/CA2380786A1/en not_active Abandoned
- 2000-08-11 NZ NZ517238A patent/NZ517238A/en unknown
- 2000-08-11 HU HU0301857A patent/HUP0301857A2/hu unknown
- 2000-08-11 WO PCT/US2000/017878 patent/WO2001012188A1/en not_active Ceased
- 2000-08-11 MX MXPA02001497A patent/MXPA02001497A/es active IP Right Grant
- 2000-08-11 AT AT00955241T patent/ATE361070T1/de not_active IP Right Cessation
- 2000-08-11 JP JP2001516534A patent/JP2003507328A/ja not_active Withdrawn
- 2000-08-11 ES ES00955241T patent/ES2284518T3/es not_active Expired - Lifetime
- 2000-08-11 SK SK208-2002A patent/SK2082002A3/sk unknown
- 2000-08-11 KR KR1020027001815A patent/KR20020060158A/ko not_active Withdrawn
-
2002
- 2002-02-08 ZA ZA200201118A patent/ZA200201118B/en unknown
- 2002-02-11 NO NO20020687A patent/NO20020687L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL354058A1 (en) | 2003-12-15 |
| HUP0301857A2 (hu) | 2003-09-29 |
| EA200200249A1 (ru) | 2002-08-29 |
| HK1049790A1 (zh) | 2003-05-30 |
| ZA200201118B (en) | 2003-05-28 |
| EP1202734A4 (en) | 2004-09-01 |
| DE60034683D1 (de) | 2007-06-14 |
| NZ517238A (en) | 2004-01-30 |
| EP1202734A1 (en) | 2002-05-08 |
| EP1202734B1 (en) | 2007-05-02 |
| CO5200848A1 (es) | 2002-09-27 |
| MXPA02001497A (es) | 2003-07-21 |
| SK2082002A3 (en) | 2002-09-10 |
| NO20020687D0 (no) | 2002-02-11 |
| IL147925A0 (en) | 2002-08-14 |
| WO2001012188A1 (en) | 2001-02-22 |
| AU6747000A (en) | 2001-03-13 |
| ATE361070T1 (de) | 2007-05-15 |
| BR0013277A (pt) | 2002-06-18 |
| KR20020060158A (ko) | 2002-07-16 |
| NO20020687L (no) | 2002-04-03 |
| CA2380786A1 (en) | 2001-02-22 |
| PE20010482A1 (es) | 2001-04-20 |
| ES2284518T3 (es) | 2007-11-16 |
| DE60034683T2 (de) | 2008-01-17 |
| JP2003507328A (ja) | 2003-02-25 |
| CN1379668A (zh) | 2002-11-13 |
| US6387900B1 (en) | 2002-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
| UY28578A1 (es) | Derivados de amida | |
| SE9904176D0 (sv) | New use | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| CR7698A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| AR022283A1 (es) | Aminas substituidas de espirofuropiridinas novedosas utiles en terapia | |
| MXPA05007496A (es) | Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes. | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| HRP20080477T3 (en) | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors | |
| AR036599A1 (es) | Un derivado de 2-pirimidinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)ona sustituidos, uso del mismo, un medicamento que lo comprende y un inhibidor de gsk3beta o gsk3beta y cdk5/p25 seleccionado entre el grupo de dicho derivado | |
| PY0225352A (es) | Nuevos derivados de piperazina | |
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
| MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2123652T3 (es) | 7-(2-aminoetil)-benzotiazolonas. | |
| DE60024604D1 (de) | Xanthinderivate und analoge als zellsignalisierung inhibitoren | |
| MXPA05007494A (es) | Nuevos compuestos. | |
| AR033879A1 (es) | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto | |
| AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |